Yabao Pharmaceuticals and Salus Pharma Announce Partnership


BEIJING & MONMOUTH JUNCTION, N.J.–Yabao Pharmaceutical Co, Inc. (Shanghai Stock Exchange 600351) and Salus Pharma LLC today announced a strategic partnership to co-develop, manufacture and commercialize high technological barrier generic drugs worldwide.

Under the terms of the agreement, Yabao will exclusively own rights to commercialize certain Salus Pharma-developed products outside the U.S. and to manufacture for worldwide markets, while Salus Pharma will retain rights to commercialize in the U.S. Financial terms were not disclosed.

Subscribe to get the latest news